Shockwave Medical, a US-based medical device firm focused on transforming cardiovascular diseases, has rolled out its Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter in the US.

Shockwave C2+ Coronary IVL catheter is designed to provide 50% more pulses per catheter.

The planned launch follows the receipt of approval from the US Food and Drug Administration (FDA).

The device’s earlier version, the Shockwave C2 catheter, was approved in the US in 2021.

Shockwave Medical plans to launch the enhanced C2+ catheter at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation next week.

The full commercial launch is expected in November this year, while introduction in select global markets was announced in May.

St. Francis Hospital, Roslyn, New York department of cardiology chairman Richard Shlofmitz said: “The enhancements of Shockwave C2+ will be an added benefit of IVL for optimally treating complex calcium, including more diffuse disease, as well as nodular and thick, eccentric calcium.

“When additional pulses are added to the existing intuitive catheter design and simple-to-use system that are foundational to the success of Shockwave IVL, the result is an updated catheter that can enhance workflow and improve procedural efficiency.”

Shockwave’s first-of-its-kind IVL technology is designed for the treatment of atherosclerotic cardiovascular disease through the safe use of sonic pressure waves. The technology disrupts difficult calcified plaque, causing significantly enhanced patient outcomes.

The Neovasc Reducer, which is CE Marked in Europe and is undergoing clinical research in the US and Canada, was also recently acquired by Shockwave.

The Reducer is intended to alleviate refractory angina in millions of patients globally by reallocating blood flow within the heart.